AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Recruiting now
Conditions studied: Pancreatic Ductal Adenocarcinoma
In brief
To collect samples and information from patients who will be undergoing standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel. The information collected will be used to determine if there are any "biomarkers" in your blood or tumor tissue that, when compared to your response to the neoadjuvant treatment, could be used to choose the best treatment option for future patients with similar biomarkers.
Key facts
- Study ID
- NCT06320717
- Run by
- Roswell Park Cancer Institute
- People needed
- 100
- Starts
- 2024-01-02
- Expected to finish
- 2026-12-02
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have histologically or cytologically confirmed PDAC that is borderline resectable (BR) (Cohort A) OR have histologically or cytologically confirmed PDAC that is resectable (Cohort B) using the National Comprehensive Cancer Network criteria [35].
- Availability of archival tumor tissue (diagnostic for PDAC) required
- Have a documented ECOG Performance Status of ≤ 1
- Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form (ICF) prior to receiving any study related procedure.
You may not qualify if…
- Has received prior systemic treatment (standard of care or experimental) for PDAC
- Participant has a concurrent malignancy requiring active treatment during the study.
Where it is running
- Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States (enrolling)
- Good Samaritan University Hospital — West Islip, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.